https://www.selleckchem.com/pr....oducts/Tipifarnib(R1
The frequency of patients with HV 1 SD was higher (p = 0.025) among patients with adherence 90%. The best model to predict the height gain(cm) reaching an adjusted R squared of 0.489 involved percentage of adherence, Tanner stage, pretreatment HV, dose of rhGH, and whether the treatment was initiated before or after puberty. Adherence during the first 2 years of response was very high 90% and showed a negative association with age, pretreatment HV and treatment duration and a positive correlation with the level
Like
Comment
Share
